References
1. Allen CE, Merad M, McClain KL. Langerhans-Cell Histiocytosis. N Engl J Med . Aug 30 2018;379(9):856-868. doi:10.1056/NEJMra1607548
2. McClain KL, Bigenwald C, Collin M, et al. Histiocytic disorders.Nat Rev Dis Primers . Oct 7 2021;7(1):73. doi:10.1038/s41572-021-00307-9
3. Krooks J, Minkov M, Weatherall AG. Langerhans cell histiocytosis in children: History, classification, pathobiology, clinical manifestations, and prognosis. J Am Acad Dermatol . Jun 2018;78(6):1035-1044. doi:10.1016/j.jaad.2017.05.059
4. Xiang C, Li H, Tang W. Targeting CSF-1R represents an effective strategy in modulating inflammatory diseases. Pharmacol Res . Jan 2023;187:106566. doi:10.1016/j.phrs.2022.106566
5. Hagan N, Kane JL, Grover D, et al. CSF1R signaling is a regulator of pathogenesis in progressive MS. Cell Death Dis . Oct 23 2020;11(10):904. doi:10.1038/s41419-020-03084-7
6. Ozkaya N, Lee I, Johnson TS, Jaffe ES. CSF1R/CD115 is a Helpful Marker for the Distinction of Florid Dermatopathic Lymphadenopathy From Langerhans Cell Neoplasms. Am J Surg Pathol . Jul 1 2023;47(7):844-846. doi:10.1097/pas.0000000000002047
7. Lonardi S, Scutera S, Licini S, et al. CSF1R Is Required for Differentiation and Migration of Langerhans Cells and Langerhans Cell Histiocytosis. Cancer Immunol Res . Jun 2020;8(6):829-841. doi:10.1158/2326-6066.Cir-19-0232
8. Barreda DR, Hanington PC, Stafford JL, Belosevic M. A novel soluble form of the CSF-1 receptor inhibits proliferation of self-renewing macrophages of goldfish (Carassius auratus L.). Dev Comp Immunol . 2005;29(10):879-94. doi:10.1016/j.dci.2005.02.006
9. Shi M, Movius J, Dator R, et al. Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation. Mol Cell Proteomics . Mar 2015;14(3):544-55. doi:10.1074/mcp.M114.040576
10. Cui L, Zhang L, Ma HH, et al. Circulating cell-free BRAF V600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis. Haematologica . Sep 1 2020;105(9):e444-447. doi:10.3324/haematol.2019.229187
11. Shi H, He H, Cui L, et al. Transcriptomic landscape of circulating mononuclear phagocytes in Langerhans cell histiocytosis at the single-cell level. Blood . Oct 7 2021;138(14):1237-1248. doi:10.1182/blood.2020009064
12. Schwentner R, Jug G, Kauer MO, et al. JAG2 signaling induces differentiation of CD14(+) monocytes into Langerhans cell histiocytosis-like cells. J Leukoc Biol . Jan 2019;105(1):101-111. doi:10.1002/jlb.1a0318-098r
13. Lone SN, Nisar S, Masoodi T, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments.Mol Cancer . Mar 18 2022;21(1):79. doi:10.1186/s12943-022-01543-7
14. Ding Z, Wang N, Ji N, Chen ZS. Proteomics technologies for cancer liquid biopsies. Mol Cancer . Feb 15 2022;21(1):53. doi:10.1186/s12943-022-01526-8
15. Budayeva HG, Kirkpatrick DS. Monitoring protein communities and their responses to therapeutics. Nat Rev Drug Discov . Jun 2020;19(6):414-426. doi:10.1038/s41573-020-0063-y
16. Murakami I, Oh Y, Morimoto A, et al. Acute-phase ITIH4 levels distinguish multi-system from single-system Langerhans cell histiocytosis via plasma peptidomics. Clin Proteomics . 2015;12(1):16. doi:10.1186/s12014-015-9089-2
17. Cui L, Wang CJ, Lian HY, et al. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study. Am J Hematol . Apr 2023;98(4):598-607. doi:10.1002/ajh.26829
18. Xiao Y, van Halteren AGS, Lei X, et al. Bone marrow-derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis. Blood . Nov 5 2020;136(19):2188-2199. doi:10.1182/blood.2020005209
19. Gushchina S, Yip PK, Parry GA, et al. Alleviation of neuropathic pain by over-expressing a soluble colony-stimulating factor 1 receptor to suppress microgliosis and macrophage accumulation. Glia . Dec 2021;69(12):2963-2980. doi:10.1002/glia.24085
20. Riddell JR, Wang XY, Minderman H, Gollnick SO. Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4.J Immunol . Jan 15 2010;184(2):1022-30. doi:10.4049/jimmunol.0901945
21. Asea A, Rehli M, Kabingu E, et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem . Apr 26 2002;277(17):15028-34. doi:10.1074/jbc.M200497200
22. Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. JAMA Oncol . Mar 1 2018;4(3):384-388. doi:10.1001/jamaoncol.2017.5029
23. Kieran MW, Geoerger B, Dunkel IJ, et al. A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors. Clin Cancer Res . Dec 15 2019;25(24):7294-7302. doi:10.1158/1078-0432.Ccr-17-3572
24. Wang D, Chen XH, Wei A, et al. Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis. Orphanet J Rare Dis . Apr 4 2022;17(1):151. doi:10.1186/s13023-022-02276-y
25. Kolenová A, Schwentner R, Jug G, et al. Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH. Blood Adv . Feb 14 2017;1(6):352-356. doi:10.1182/bloodadvances.2016003533
26. Gulati N, Allen CE. Langerhans cell histiocytosis: Version 2021.Hematol Oncol . Jun 2021;39 Suppl 1(Suppl 1):15-23. doi:10.1002/hon.2857
27. Donadieu J, Larabi IA, Tardieu M, et al. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin Oncol . Nov 1 2019;37(31):2857-2865. doi:10.1200/jco.19.00456
28. Eckstein OS, Visser J, Rodriguez-Galindo C, Allen CE. Clinical responses and persistent BRAF V600E(+) blood cells in children with LCH treated with MAPK pathway inhibition. Blood . Apr 11 2019;133(15):1691-1694. doi:10.1182/blood-2018-10-878363
29. Wen J, Wang S, Guo R, Liu D. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment. Eur J Med Chem . Jan 5 2023;245(Pt 1):114884. doi:10.1016/j.ejmech.2022.114884
30. Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Rüttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer . Jul 18 2017;5(1):53. doi:10.1186/s40425-017-0257-y